ライフサイエンスコーパス: intraocular

1 To determine the intraocular and systemic risk factor differences between

2 ic innervation may be modulated by suggested intraocular axonal collaterals of ipRGCs traveling to th

3 novel oral anticoagulants reduce the risk of intraocular bleeding by approximately one-fifth compared

4 associated with a 22% relative reduction in intraocular bleeding compared with warfarin (risk ratio,

5 Intraocular bleeding events and associated risk ratio fo

6 Data on intraocular bleeding were pooled using inverse-variance,

7 To characterize the risk of intraocular bleeding with novel oral anticoagulants comp

8 It is unclear if the risk of intraocular bleeding with novel oral anticoagulants diff

9 Comparably lower risks of intraocular bleeding with novel oral anticoagulants were

10 n) with warfarin, and recorded event data on intraocular bleeding.

11 taracts, diabetic retinopathy, glaucoma, and intraocular cancers.

12 ildren treated using bilateral or unilateral intraocular collamer lens (Visian ICL) implantation for

13 Importance: Intraocular collamer lenses (ICLs) are posterior chamber

14 In the absence of an intraocular component, diagnosis may be challenging, as

15 In subjects with DME, sustained intraocular delivery of FAc slows development of PDR and

16 Effective intraocular drug delivery poses a major challenge due to

17 ate for further development of a sustainable intraocular drug delivery system to protect RGCs, which

18 We aim to develop an RGC-targeted intraocular drug delivery system using unimolecular mice

19 Ps) are promising drug carrier platforms for intraocular drug delivery.

20 We sought to study and evaluate the intraocular environment (aqueous and vitreous humors), t

21 conjunctival relapse, no further episodes of intraocular/extraocular recurrence were recorded, and al

22 In 3 intraocular fluid samples for IOLs with biofilm, we iden

23 trasound, angioinhibitory drugs, vitrectomy, intraocular gases, and many others.

24 To describe the clinical characteristics of intraocular hemorrhages (IOHs) in infants in the Telemed

25 recovery in the majority of individuals with intraocular hemorrhages secondary to traumatic brain inj

26 -gauge or 23-gauge pars plana vitrectomy for intraocular hemorrhages secondary to traumatic brain inj

27 valuate visual outcomes after vitrectomy for intraocular hemorrhages secondary to traumatic brain inj

28 ll male) underwent pars plana vitrectomy for intraocular hemorrhages secondary to traumatic brain inj

29 enous fungal endophthalmitis (EFE), a severe intraocular infection caused by hematogenous seeding of

30 ten included chronic recurrent or persistent intraocular inflammation and frequently required removal

31 In this paper, we report a case of intraocular inflammation during tularemia infection.

32 In December, 2015, 15 cases of intraocular inflammation following injections of counter

33 The FAi effectively controlled intraocular inflammation in all eyes in the study, and a

34 considered in the differential diagnosis of intraocular inflammation in areas where F. tularensis is

35 Overall intraocular inflammation rates were 2.37 (control) and 2

36 ilure, defined according to a multicomponent intraocular inflammation score that was based on the Sta

37 due to other potential etiologies of chronic intraocular inflammation such as implant-induced chafing

38 ere possibly study-drug related: pyrexia and intraocular inflammation that resolved with a topical st

39 Significant intraocular inflammation was not uncommon.

40 on of more than 30 diseases characterized by intraocular inflammation.

41 halmitis in any case of recurrent, low-grade intraocular inflammation.

42 ninfectious uveitis (NIU) is a collection of intraocular inflammatory disorders that may be associate

43 nd Abeta40 peptides fused to BRI2 protein by intraocular injection in C57BL/6J mice.

44 Intraocular injection of microbeads was made in mouse ey

45 sed by pericyte depletion are phenocopied by intraocular injection of VEGF-A or pericyte-specific ina

46 n that can develop after cataract surgery or intraocular injection.

47 the retina for almost 1 month after a single intraocular injection.

48 Nonetheless, optimal visual outcomes require intraocular injections as frequently as every month.

49 hilean Tinamou (Nothoprocta perdicaria) that intraocular injections of Cholera Toxin B subunit retrog

50 Long-term intraocular injections of vascular endothelial growth fa

51 itating continued neutralization by repeated intraocular injections of VEGF antagonists in many patie

52 778 15 mg twice per day (BID) + monthly sham intraocular injections; (2) combination therapy: subcuta

53 Although intraocular involvement is frequent in PCNSL and clinica

54 Exclusion criteria were intraocular involvement, orbital lymphoma, or other syst

55 short-term visual outcomes of a new trifocal intraocular lens (AcrySof PanOptix).

56 Initial undercorrection of intraocular lens (IOL power) is a common practice in chi

57 The 9 patients (56%) who had intraocular lens (IOL) and capsular bag removals had bet

58 To compare the accuracy of intraocular lens (IOL) calculation formulas (Barrett Uni

59 equirements in patients with late in-the-bag intraocular lens (IOL) dislocation operated with 2 diffe

60 y of 2 operation methods for late in-the-bag intraocular lens (IOL) dislocation.

61 Scleral intraocular lens (IOL) fixation is an accepted treatment

62 a or luxated or subluxated posterior chamber intraocular lens (IOL) following complicated cataract su

63 niques for fixation of the posterior chamber intraocular lens (IOL) have been developed.

64 Toric intraocular lens (IOL) implantation can be an effective

65 t 5 years of age after cataract surgery with intraocular lens (IOL) implantation for infants enrolled

66 nisometropia at age 5 years after unilateral intraocular lens (IOL) implantation in infants.

67 urface-based method, in candidates for toric intraocular lens (IOL) implantation.

68 on was combined with phacoemulsification and intraocular lens (IOL) implantation.

69 abbit eyes, leading to successful in-the-bag intraocular lens (IOL) implantation.

70 uare-edge (SE) polymethylmethacrylate (PMMA) intraocular lens (IOL) modification in comparison with a

71 the accuracy and reproducibility of the VRF intraocular lens (IOL) power calculation formula with we

72 sented here aims to optimize the accuracy of intraocular lens (IOL) power calculations in patients af

73 meters respond to cycloplegia, and therefore intraocular lens (IOL) power measurements calculated by

74 treous humors), the capsular tissue, and the intraocular lens (IOL) surfaces of normal eyes after lon

75 formance after implantation of a quadrifocal intraocular lens (IOL).

76 ), silicone oil removal (n = 16), dislocated intraocular lens (n = 10), submacular hemorrhage (n = 7)

77 tion and implantation of a posterior chamber intraocular lens (n = 33) using prestripped donor tissue

78 Phakic intraocular lens (PIOL) implantation has been used to co

79 To compare the outcomes after toric intraocular lens (tIOL) or peripheral corneal relaxing i

80 nd treatment modality (contact lens [CL] vs. intraocular lens [IOL]).

81 intraocular lens, 1.43 for anterior chamber intraocular lens [IOL], 2.83 for aphakic eyes; P < 0.001

82 In-the-bag intraocular lens dislocation is an uncommon but serious

83 0.25+/-0.41 logMAR at the final visit after intraocular lens implantation (p=0.000).

84 ed with most intraocular surgeries including intraocular lens implantation after cataract removal, it

85 neventful phacoemulsification and in-the-bag intraocular lens implantation on intraocular pressure co

86 rized as having had phacoemulsification with intraocular lens implantation vs no cataract surgery at

87 Intraocular lens implantation was completed in 56 eyes;

88 nd anterior vitrectomy combined with primary intraocular lens implantation were included.

89 ery with bilateral implantation of the study intraocular lens in a private practice clinic were consi

90 plant and underwent phacoemulsification with intraocular lens placement.

91 o earlier than 3 months post SB surgery, and intraocular lens power calculation with a fourth-generat

92 ular opacification, epiretinal membrane, and intraocular lens subluxation.

93 xtraction and randomization to receipt of an intraocular lens vs being left aphakic for the first 5 y

94 The intraocular lens was stable and centered at the last fol

95 eceiving bilateral implantation of the study intraocular lens were analysed.

96 vs. phakic eyes: 1.15 for posterior chamber intraocular lens, 1.43 for anterior chamber intraocular

97 requently required removal of ocular device (intraocular lens, glaucoma implant, or scleral buckle).

98 ce of and risk factors for calcifications of intraocular lenses (IOLs) after Descemet membrane endoth

99 months of 2 diffractive (non-toric) trifocal intraocular lenses (IOLs) in a large series of patients.

100 troduction of phacoemulsification and use of intraocular lenses (IOLs), both very controversial when

101 tion of 2 types of rigid iris-fixated phakic intraocular lenses (pIOLs) for the treatment of myopia a

102 New trifocal intraocular lenses have been developed to try and fullfi

103 th the development of advanced technology in intraocular lenses, the combined treatment of cataract a

104 nufacturers in designing suitable contact or intraocular lenses.

105 ird (n = 64; 38%) of original approvals were intraocular lenses.

106 Intraocular levels of VEGF are elevated in patients with

107 al diameter of tumor [LBD], tumor thickness, intraocular location of tumor, melanoma cytomorphologic

108 system lymphoma (PCNSL) is caused mostly by intraocular lymphomatous involvement (vitritis and retin

109 onfirmed tissue diagnosis of ECD that showed intraocular manifestations and were imaged at baseline a

110 Intraocular manifestations are rarely observed in associ

111 Rare intraocular manifestations of ECD confirmed on histopath

112 Intraocular manifestations of ECD seen on multimodal ima

113 To report intraocular manifestations of Erdheim-Chester Disease (E

114 sives (normal disc, normal visual field, and intraocular pressure >22 mmHg).

115 Postoperative elevation in intraocular pressure (>/=30 mmHg) was documented in 3 ey

116 excavation (20%), relatively low (<10 mmHg) intraocular pressure (22%), and optic nerve hypoplasia (

117 The mean highest intraocular pressure (32.2+/-9.7 vs. 17.6+/-3.6 mmHg; P

118 the need for repeat surgery or uncontrolled intraocular pressure (IOP) >22 mm Hg, despite topical/sy

119 Success was defined with 3 criteria: (1) intraocular pressure (IOP) </= 21 mm Hg and IOP reductio

120 levels of success criteria were defined: (A) intraocular pressure (IOP) </=18 mm Hg and IOP reduction

121 ords and classified into subtypes defined by intraocular pressure (IOP) (>/=22 or <22 mm Hg) or by vi

122 jects had POAG with mean diurnal unmedicated intraocular pressure (IOP) 21-33 mmHg and were undergoin

123 ersible vision loss worldwide, with elevated intraocular pressure (IOP) a major risk factor.

124 To examine risk factors for low intraocular pressure (IOP) after trabeculectomy and to d

125 Intraocular pressure (IOP) and cataract formation were d

126 e-dependent effect on the difference between intraocular pressure (IOP) and intracranial pressure (IC

127 To compare intraocular pressure (IOP) and IOP-lowering treatment re

128 Intraocular pressure (IOP) and optic nerve head characte

129 To determine the incidence of elevated intraocular pressure (IOP) and secondary glaucoma in her

130 m Aluminium Garnet) laser capsulotomy on the intraocular pressure (IOP) and the trabeculectomy bleb i

131 tio greater than or equal to 0.6 with normal intraocular pressure (IOP) and visual fields.

132 The outcome of interest was intraocular pressure (IOP) at 3 months.

133 OBSERVATION: Intraocular pressure (IOP) at the end of the surgery, im

134 nstrate that DBA/2J.Wld(s) mice develop high intraocular pressure (IOP) but are protected from retina

135 mechanism to effectively treat glaucomatous intraocular pressure (IOP) dysregulation.

136 k (TM) is associated with TM dysfunction and intraocular pressure (IOP) elevation in glaucoma.

137 Intraocular pressure (IOP) elevation was relatively rapi

138 Upon intraocular pressure (IOP) elevation, CSS appeared hyper

139 The baseline intraocular pressure (IOP) for SLT 1 = 20.3+/- 5.2 mmHg

140 of vision loss or blindness and reduction of intraocular pressure (IOP) has been proven beneficial in

141 nometry (GAT) error relative to intracameral intraocular pressure (IOP) has not been examined compara

142 y/Phacoviscocanalostomy (VC/PVC) in lowering intraocular pressure (IOP) in Normal Tension Glaucoma (N

143 ciations between systemic medication use and intraocular pressure (IOP) in the general population.

144 Postoperative complications were intraocular pressure (IOP) increase (n = 12), cystoid ma

145 Elevated intraocular pressure (IOP) is a major risk factor for gl

146 Accurate determination of intraocular pressure (IOP) is crucial for the diagnosis

147 Intraocular pressure (IOP) is maintained as a result of

148 In the eye, intraocular pressure (IOP) is tightly regulated and its

149 experience disease progression at different intraocular pressure (IOP) levels to aid clinicians with

150 normotensive glaucoma rabbit model for their intraocular pressure (IOP) lowering effects and showed i

151 The mean intraocular pressure (IOP) measured with Goldmann Applan

152 ects also had to be able to obtain the first intraocular pressure (IOP) measurement within 5 mmHg of

153 , and family history; visual acuity testing, intraocular pressure (IOP) measurement, and corneal pach

154 libercept group included 4 participants with intraocular pressure (IOP) more than 10 mm Hg greater th

155 is the rate of surgical failure, defined as intraocular pressure (IOP) more than 21 mmHg or reduced

156 of persistent appositional angle closure and intraocular pressure (IOP) of more than 21 mmHg were enr

157 The primary outcome was failure, defined as intraocular pressure (IOP) outside the target range (5-1

158 ilure, with failure defined as 2 consecutive intraocular pressure (IOP) readings of <6 mmHg with visi

159 The mean intraocular pressure (IOP) recorded at the pre-switch vi

160 Primary outcome measure was intraocular pressure (IOP) reduction.

161 Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need.

162 aucoma has been established by elevating the intraocular pressure (IOP) via microbead occlusion of oc

163 s of data, increased fellow eye preoperative intraocular pressure (IOP) was associated with decreased

164 Baseline intraocular pressure (IOP) was measured with a tonometer

165 s administered to 5 normotensive rabbits and intraocular pressure (IOP) was monitored for 28 days.

166 Blood pressure and intraocular pressure (IOP) were measured in the sitting

167 ICP and intraocular pressure (IOP) were simultaneously measured

168 The ability of patients to measure their own intraocular pressure (IOP) would allow more frequent mea

169 ilure or last visit, surgical details, final intraocular pressure (IOP), and complications were recor

170 CH, central corneal thickness (CCT), average intraocular pressure (IOP), and rates of RNFL loss durin

171 Intraocular pressure (IOP), as assessed by tonopen, was

172 ma Index (GI) that incorporated preoperative intraocular pressure (IOP), number of medications and vi

173 ange of best-corrected visual acuity (BCVA), intraocular pressure (IOP), pupillary aperture, glare, c

174 Elevated intraocular pressure (IOP), which causes optic nerve dam

175 To evaluate the safety and intraocular pressure (IOP)-lowering effect of a biodegra

176 The purpose of this study was to compare intraocular pressure (IOP)-lowering efficacy and safety

177 % improved tolerability while retaining the intraocular pressure (IOP)-lowering efficacy of bimatopr

178 To characterize the 12-month intraocular pressure (IOP)-lowering efficacy of selectiv

179 To evaluate the intraocular pressure (IOP)-lowering performance and safe

180 Accurate prediction of the intraocular pressure (IOP)-lowering response in the fell

181 o maintain normal aqueous humor drainage and intraocular pressure (IOP).

182 etic mutation causing glaucoma by increasing intraocular pressure (IOP).

183 l retinal detachment; (6) hypotony/increased intraocular pressure (IOP); (7) macula pucker/epiretinal

184 Nitric oxide (NO) is able to lower intraocular pressure (IOP); however, its therapeutic eff

185 ords and classified into subtypes defined by intraocular pressure (IOP; >/= or <22 mmHg) or visual fi

186 49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P =

187 tically significant reductions from baseline intraocular pressure (P < .001), and was noninferior to

188 d newly diagnosed primary angle closure with intraocular pressure 30 mm Hg or greater or primary angl

189 Postoperative success (intraocular pressure [IOP] < 22 mm Hg +/- glaucoma medic

190 rimary outcome measure was surgical success (intraocular pressure [IOP] </=21 mmHg and reduced >/=20%

191 Cumulative failure rates (using an intraocular pressure [IOP] target of 6-18 mm Hg inclusiv

192 and place of residence), ocular parameters (intraocular pressure [IOP], axial length and mean ocular

193 (age, sex, central corneal thickness [CCT], intraocular pressure [IOP], refraction, medications), as

194 new candidate gene, Cacna2d1, that modulates intraocular pressure and a promising therapeutic, pregab

195 Also close monitoring of the intraocular pressure and assessment of eventual bleb mor

196 uate the etiopathologic relationship between intraocular pressure and ocular biometric parameters and

197 ations of the metabolic syndrome (MetS) with intraocular pressure and primary open angle glaucoma (OA

198 k is potentially an important determinant of intraocular pressure and success of trabecular bypass gl

199 microbeads was made in mouse eyes to elevate intraocular pressure as a model of experimental glaucoma

200 Elevated intraocular pressure as the result of abnormal resistanc

201 Torsional power was set at 60% and intraocular pressure at 50 mm Hg.

202 formed after one year of follow-up regarding Intraocular pressure changes, bleb morphology score usin

203 in-the-bag intraocular lens implantation on intraocular pressure control and the bleb morphology in

204 uccessfully placed in both eyes and adequate intraocular pressure control was achieved for 4 months.

205 Secondary outcomes included intraocular pressure control, worsening of visual acuity

206 This sustained elevated intraocular pressure could lead to higher rates of glauc

207 lowing pilocarpine administration, mean (SD) intraocular pressure decreased from 14.3 (1.3) to 13.7 (

208 unction (91.2% to 96.1%, P < .02) and target intraocular pressure determination (73.7% to 83.2%, P <

209 ive uveitis (r = -0.41; P < 0.0001), maximum intraocular pressure during the course of disease (r = -

210 e the most vulnerable to transient transient intraocular pressure elevation as measured by rates of c

211 for the first time, the effects of transient intraocular pressure elevation on the structure and func

212 Intraocular pressure elevation was not observed in exper

213 Intraocular pressure elevation was the second most commo

214 ur early, within 14 d after acute, transient intraocular pressure elevation, have not been previously

215 At the last visit, the mean intraocular pressure for the temporal group was 17.55 +/

216 Outcome measures included reduction in intraocular pressure from baseline, survival analysis, a

217 oprietary hypotensive agent, DE-117, reduced intraocular pressure in normotensive rabbits significant

218 Elevated intraocular pressure is a highly heritable risk factor f

219 Treatment to lower intraocular pressure is based on topical drugs, laser th

220 Progression usually stops if the intraocular pressure is lowered by 30-50% from baseline.

221 In early-stage disease, intraocular pressure is raised without visual loss.

222 Complications included elevated intraocular pressure leading to glaucoma; cataracts, inc

223 We demonstrate that high intraocular pressure leads to a rapid increase in endoge

224 Topical intraocular pressure lowering therapy had to be re-initi

225 Visual acuity assessment, intraocular pressure measurement, and fundus examination

226 ected visual acuity, slitlamp biomicroscopy, intraocular pressure measurement, gonioscopy, dilated op

227 al atropine with different concentrations on intraocular pressure measurements and myopia progression

228 mily history of glaucoma, visual acuity, and intraocular pressure measurements using the ICare reboun

229 Intraocular pressure measurements were performed with GA

230 ly, and there was no significant increase in intraocular pressure observed until the 10-year follow-u

231 A mild transient rise in intraocular pressure occurred in 3 out of 8 eyes.

232 raocular surgery or refractory glaucoma with intraocular pressure of >18 mm Hg.

233 vitreous haze score, and presence of raised intraocular pressure or cataract.

234 Oxidative stress contributes to both intraocular pressure regulation and glaucomatous neuropa

235 , which binds to CACNA2D1 protein and lowers intraocular pressure significantly.

236 es of 22 PAC patients with a history of high intraocular pressure underwent imaging with OCT.

237 Mean change from baseline intraocular pressure was +2.6 vs +1.7 mm Hg (P = .52).

238 The intraocular pressure was 15 mm Hg postoperatively, and t

239 Mean intraocular pressure was 20 mm Hg (median, 16; range, 15

240 Intraocular pressure was controlled with systematic addi

241 Intraocular pressure was measured using Goldmann applana

242 previously analyzed clinical measures (i.e., intraocular pressure).

243 sistance of the aqueous drainage tissues and intraocular pressure, a key pathogenic factor of glaucom

244 al acuity, perimetry, slit-lamp examination, intraocular pressure, and fundus photography.

245 netic and molecular mechanisms that regulate intraocular pressure, and identifies a new candidate gen

246 s, larger vertical cup-to-disc ratio, higher intraocular pressure, and self-reported black race were

247 outcomes included changes in visual acuity, intraocular pressure, and trends in scleral grading.

248 Clinical data, including systemic disorders, intraocular pressure, and visual outcomes were recorded.

249 l examination (best-corrected visual acuity, intraocular pressure, biomicroscopic examination of the

250 ral or clear superior wound, does not affect intraocular pressure, bleb morphology or function after

251 ured included GCC thickness, autorefraction, intraocular pressure, blood pressure, body mass index, a

252 otential ocular side effects (e.g., elevated intraocular pressure, cataracts).

253 those seen in single oil tamponade (elevated intraocular pressure, cystoid macular oedema (CMO), cata

254 se the common causal risk factor of elevated intraocular pressure, delay, but cannot prevent, RGC dea

255 common cause for postoperative elevation of intraocular pressure, especially in children.

256 mplex thickness was not associated with sex, intraocular pressure, or diabetes.

257 form of glaucoma-include older age, elevated intraocular pressure, sub-Saharan African ethnic origin,

258 ent including ocular massage and lowering of intraocular pressure, the visual loss remained.

259 esultant transudation of fluid and increased intraocular pressure, thereby leading to secondary glauc

260 Age, sex, intraocular pressure, visual field (VF) mean deviation (

261 d clinical data, including visual acuity and intraocular pressure, were obtained at enrollment and fr

262 variants, we are able to determine that the intraocular pressure-lowering effect of pregabalin is de

263 Intraocular pressure-related parameters obtained with 24

264 m a severely hypomorphic canal with elevated intraocular pressure.

265 s optic neuropathy despite a well-controlled intraocular pressure.

266 and visual loss, death of participants, and intraocular pressure.

267 are associated with a sustained increase in intraocular pressure.

268 ighlight the importance of proper control of intraocular pressure.

269 t to the cornea and lens, and by maintaining intraocular pressure.

270 he plasma into the aqueous humor, increasing intraocular pressure.

271 indness that occurs without grossly abnormal intraocular pressure.

272 eous humor outflow and maintenance of normal intraocular pressure.

273 ng, visual field testing, and measurement of intraocular pressure.

274 a, photophobia, and blepharospasm; increased intraocular pressure; corneal clouding at birth; and bup

275 man immunodeficiency virus (HIV) and reduced intraocular pressures (IOP).

276 Prevalent and incident OHT with intraocular pressures (IOPs) of >/=21 mmHg, >/=30 mmHg,

277 had improved to 20/60 OD and 20/25 OS, with intraocular pressures of 18 mm Hg OD and 19 mm Hg OS.

278 No difference in intraocular pressures was detected between Tg-TBK1 mice

279 y resected iris melanoma, without concurrent intraocular recurrence.

280 None showed intraocular relapse.

281 dition TNMH cancer staging and International Intraocular Retinoblastoma Classification (IIRC), and nu

282 ich suggest that children with International Intraocular Retinoblastoma Classification group E retino

283 Intraocular retinoblastoma is curable, but survivors wit

284 valuate topotecan-based therapy for advanced intraocular retinoblastoma.

285 ndophthalmitis has been associated with most intraocular surgeries including intraocular lens implant

286 eyes (21.0%) underwent at least 1 additional intraocular surgery in the follow-up period, most common

287 -six subjects aged 18-85 years with previous intraocular surgery or refractory glaucoma with intraocu

288 ter retinal changes without prior history of intraocular surgery or uveitis should prompt further eva

289 -grade uveitis several weeks or months after intraocular surgery which may be responsive to corticost

290 in 20 of 151 glaucoma eyes (13.2%) (12 prior intraocular surgery, 5 uveitis, 3 primary retinopathy) a

291 ter excluding participants with a history of intraocular surgery, a diagnosis of glaucoma suspect or

292 al dysfunction, especially in the setting of intraocular surgery.

293 ntion time and low penetration capacity into intraocular tissues are the key obstacles that hinder th

294 However, tumor LBD, tumor thickness, and intraocular tumor location also proved to be significant

295 Uveal melanoma (UM) is a rare intraocular tumor that, similar to cutaneous melanoma, o

296 This led to the discovery of a multicystic intraocular tumor.

297 d studied the methylome in the most frequent intraocular tumors in adults and children (uveal melanom

298 We then co-injected (mice, intraocular) unimNPs with the glutamate analog N-methyl-

299 All eyes received intraocular vancomycin via intracameral bolus (33/36), v

300 ll cases in this series were associated with intraocular vancomycin.

301 So far a correlation of intraocular VEGF concentrations to the impact of the pat